Home › Funds › Citadel Advisors › GLTO
Citadel Advisors position in GLTO
DAMORA THERAPEUTICS INC
Latest position (Q2 2026)166.35K sh
Reported value held$4.33M
Portfolio Weight0.00%
First reportedQ4 2021
Last changeNew
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q4 2021 | 12.90K | $39.00K | New |
| Q1 2023 | 14.85K | $29.55K | New |
| Q2 2023 | 16.04K | $40.41K | Add |
| Q4 2023 | 74.73K | $53.81K | New |
| Q1 2024 | 124.30K | $96.95K | Add |
| Q2 2024 | 128.78K | $61.08K | Add |
| Q2 2026 | 166.35K | $4.33M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
Other funds holding GLTO
- Fidelity Management & Research (FMR) 9.23M sh · $240.15M · Q2 2026
- BlackRock Inc 3.16M sh · $82.25M · Q2 2026
- Viking Global Investors 2.31M sh · $60.11M · Q2 2026
- JPMorgan Chase & Co 2.06M sh · $49.85M · Q2 2026
- Balyasny Asset Management 1.23M sh · $31.97M · Q2 2026
- Wellington Management Group 1.06M sh · $27.52M · Q2 2026
- Geode Capital Management 965.36K sh · $25.11M · Q2 2026
- UBS Group AG 840.29K sh · $21.86M · Q2 2026
- Northern Trust Corp 359.70K sh · $9.36M · Q2 2026
- Goldman Sachs Group 339.38K sh · $8.83M · Q2 2026
- BNY Mellon 151.02K sh · $3.93M · Q2 2026